News

EHF 2020 | Call for abstracts Dear colleagues and friends, We herewith cordially invite you to the 14th Congress of the European Headache Federation in Berlin. New and exciting times are dawning, with […]

Galcanezumab (Emgality) Gets FDA OK for Cluster Headache Megan Brooks June 04, 2019 The US Food and Drug Administration (FDA) has approved the calcitonin gene-related peptide (CGRP) antagonist galcanezumab-gnlm (Emgality, Eli Lilly […]

Abstract Submission is now open For submitting your abstract, click Here.

EHF Announcements Dear all, It was a pleasure meeting most of you last week during congress in Athens – we would like to take the opportunity to invite you to […]

please click Here to Challenge Yourself, Build Your Knowledge

Lasmiditan for acute treatment of migraine. for more information please click Here.

IHS – Short Stay Scholarships  Initiative for Improving Headache Practice, Research and Education in Developing Countries The IHS Board of Trustees, together with the IHS Juniors Group, welcomes applications for […]

please click Here to Challenge Yourself, Build Your Knowledge  

Please click Here to Challenge Yourself, Build Your Knowledge  

Background and scope of the school Globally, headache has been reported as the 7th cause of disability. This scientific meeting provides the most useful information on most primary and some secondary […]